Compare AIRS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRS | KZIA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.4M | 186.7M |
| IPO Year | 2021 | 2002 |
| Metric | AIRS | KZIA |
|---|---|---|
| Price | $1.42 | $7.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.50 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 838.4K | 261.5K |
| Earning Date | 11-06-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $151,818,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $4.86 |
| 52 Week High | $12.00 | $17.40 |
| Indicator | AIRS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 28.65 |
| Support Level | N/A | $6.82 |
| Resistance Level | $2.03 | $8.18 |
| Average True Range (ATR) | 0.13 | 0.63 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 5.43 | 20.05 |
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.